About Sirona Management

Howard J. Verrico, MD
CEO and Chairman of the Board
V-card

Dr. Verrico obtained his medical degree from the University of Toronto in 1985 and has been a member of the College of Physicians and Surgeons of British Columbia since July 1986. Dr Verrico is currently a practicing emergency room physician. In addition, Dr. Verrico has extensive experience as a venture capitalist in the junior capital markets.

Géraldine Deliencourt-Godefroy, PhD
Chief Scientific Officer
V-card

Dr. Géraldine Deliencourt-Godefroy is an award-winning synthetic chemist and the founder of French-based biotechnology company TFChem. Since the acquisition of TFChem by Sirona Biochem in March 2011, Dr. Deliencourt-Godefroy has assumed the role of Chief Scientific Officer. Her scientific research in carbohydrate chemistry has led to the discovery of new drug families and the development of drug candidates for diabetes and obesity, cosmetic ingredients and biological adjuvants. Previous to founding TFChem, Dr. Deliencourt-Godefroy was a scientific leader at INSA (National Institute of Applied Sciences) in Rouen, France, where she developed a new technology on stabilized carbohydrates. Previous roles also include a post-doctoral position at the University College London and doctoral research at the Research Institute of Fine Organic Chemistry in Rouen, France. Dr. Deliencourt-Godefroy received a PhD and Masters in Organic Chemistry as well as her business degree from the University of France. She is the author of several publications and patents and is also the recipient of the acclaimed Francinov Research and Innovation Medal, French Ministry of Research Award and the French Senate Award.

Christopher Hopton, CGA
Chief Financial Officer
V-card

Christopher Hopton is Sirona Biochem’s Chief Financial Officer. He brings 25 years of expertise in financial management and operations. His extensive experience covers areas of financial planning, accounting policy and business process improvement. As a business investment and finance consultant, Mr. Hopton has worked with several public and privately-held companies. Most recently, Mr. Hopton was the Chief Financial Officer of Central Resources Corp., a junior mineral exploration company. Formerly, he held the position of Division Controller at Canadian Airlines where he was responsible for an annual operating budget of $200M. Mr. Hopton was also involved in the restructuring of 360 Networks, a network communications company, which led to a buyout by Bell Canada. Mr. Hopton earned his Bachelor of Business Administration from Simon Fraser University in British Columbia, Canada and received his professional designation as a Certified General Accountant.

Seltenrich-head shot-smallMichelle Seltenrich, MBA
Vice President, Operations
V-card

Michelle Seltenrich brings 15 years of experience in publicly traded biotech companies. Her experience ranges from pharmaceutical lab management to corporate development in mergers/acquisitions. Ms. Seltenrich was previously Manager of Business Development at Forbes MediTech and was responsible for international business development, in-licensing and M&A. She worked with senior management in M&A recommendation and played a key role in the successful  acquisition of a U.S. based biotech company.  Ms. Seltenrich holds a BSc from the University of British Columbia and an MBA in Technology Management from Simon Fraser University.

 

Aleksandra Kasikovic, MSc
Manager, Commercial Development
V-card

Aleksandra Kasikovic holds both a MSc in Biotechnology and BSc in Biology and Marketing from McGill University. Her early exposure to the field of biotechnology fueled her desire to work towards a career in the industry. Through her research experience in different North American laboratories, both chemistry and biology based, and hands-on communications, management and marketing work, Aleksandra has developed an understanding of both the scientific and business side of this industry.

 

Product Development

While carbohydrate-based molecules offer immense commercial potential, we are focusing on three programs at this time.